Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Celgene's drug for anemia in beta thalassemia priced at $3,441/ 25 mg vial [Reuters (UK)]

Acceleron Pharma Inc. (XLRN) 
Last acceleron pharma inc. earnings: 2/27 04:05 pm Check Earnings Report
Company Research Source: Reuters
Celgene's drug for anemia in beta thalassemia priced at $3,441/ 25 mg vial - Reuters 2 Min Read (Reuters) - Celgene Corp’s treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc said. The U.S. Food and Drug Administration approved the treatment, Reblozyl, on Friday. The drug was jointly developed by Acceleron and Celgene, which is being bought by Bristol-Myers Squibb Co. A typical dose of Reblozyl consists of 1 mg of the drug for a kilogram of patient’s weight. A 75 mg vial of Reblozyl will be available at a wholesale acquisition cost of $10,323.53 per vial, Acceleron said. The drug is expected to be available a week following the approval. Acceleron will co-promote Reblozyl with Celgene in North America, while Celgene will be responsible for the drug’s commercialization outside of North America. Bristol-Myers had announced in early January that it planned to buy Celgene Show less Read more
Impact Snapshot
Event Time:
XLRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for XLRN alerts
Opt-in for
XLRN alerts

from News Quantified
Opt-in for
XLRN alerts

from News Quantified